Strategies to incorporate left atrial appendage occlusion into clinical practice

Area of Science:

• Cardiology
• Medical Devices
• Interventional Cardiology

Background:

• The left atrial appendage (LAA) is a primary source of thrombus in nonvalvular atrial fibrillation (NVAF), leading to thromboembolic events.
• Medical therapy has been the long-standing treatment, but mechanical LAA occlusion is a developing alternative.
• The Watchman device represents the most studied option, recently FDA-approved for select US patients.

Purpose of the Study:

• To provide guidance for healthcare institutions and operators establishing LAA occlusion programs.
• To offer insights into optimizing patient selection, procedural techniques, and patient outcomes.
• To address the lack of current guidelines for implementing LAA occlusion therapy.

Main Methods:

• This perspective synthesizes existing data and clinical experience.
• It explores key considerations for program development and patient management.
• Focuses on practical information for successful LAA occlusion program implementation.

Main Results:

• The Watchman device has the most extensive data supporting its use in LAA occlusion.
• Successful LAA occlusion programs require careful attention to patient selection and procedural execution.
• Optimized programs aim to minimize thromboembolic events and improve patient outcomes.

Conclusions:

• LAA occlusion is a viable therapeutic option for selected NVAF patients at risk of stroke.
• Establishing comprehensive LAA occlusion programs is crucial for maximizing therapeutic benefits.
• Further guidance and standardization are needed to support the widespread adoption of LAA occlusion therapy.